GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... planning launches for five major new product approval opportunities next ...

and GSK. During her years at Havas, Laura demonstrated an impressive ability to lead transformative brand initiatives, including a major rebrand for the American Cancer Society, which redefined the ...

The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...

European stocks followed Asian peers lower amid a deluge of earnings, on a day fraught with risks including the UK budget and ...

Haleon, the two-year-old CPG spinoff from GSK, is not only leading in marketing ... Inclusive” over-the-counter U.S. health brands as announced this week by the SeeMe Index.

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.

The Kigali Amendment to the Montreal Protocol is pushing major pharmaceutical companies ... benefit the companies’ bottom lines. GSK’s fast-acting brand-name albuterol inhaler, Ventolin ...

By enhancing DEI strategies, UK firms can set themselves apart, fostering inclusivity that drives growth – Reshma Sheikh ...

With brands that include its namesake ... insulates the company from problems with any one product. We expect GSK to be a major competitor in respiratory, HIV, and vaccines over the next decade.

Now, there are fewer major points of uncertainty for those considering ... assuming it can't get one of its collaborators, like GSK, to fund further efforts. People who buy the stock today are ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...